Cardio-Renal-Metabolic connection – Do we have possibilities for solving this problem?

7th International Congress of Cardionephrology KARNEF (2025) [pp. 182-194]

AUTHOR(S) / АУТОР(И): Andrew J. Krentz 

Download Full Pdf   

DOI: 10.46793/KARNEF25.190K

ABSTRACT / САЖЕТАК:

Within the continuum of cardiometabolic diseases, a cardiovascular-kidney-metabolic (CKM) syndrome has been conceptualised. The CKM syndrome is a systemic disorder characterised by pathophysiological interactions between metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system.  CKM syndrome is characterised by multiorgan dysfunction and confers a high risk of adverse cardiovascular outcomes. Relevant haemodynamic and neurohormonal pathologies of the include the metabolic syndrome (central adiposity, insulin resistance, hypertension, hyperglycaemia, atherogenic dyslipidaemia), overactivity of the renin-angiotensin-aldosterone system (RAAS), oxidative stress, and systemic inflammation.  The American Heart Association subdivides CKM syndrome into five stages according to risk factors and manifestations of the syndrome.  Stage 0 is defined as having no risk factors for CKM and offers opportunities for primordial prevention.  By stage 4, cardiovascular disease (CVD) is clinically evident in concert with metabolic risk factors.  Stage 4 is partitioned by (a) the absence or (b) presence of chronic kidney disease (CKD).  An interdisciplinary approach to clinical care is recommended.  For each CKM stage, personalised management options are recommended to manage the syndrome and/or to prevent disease progression.  Phenotypic heterogeneity is recognised which further complicates optimal prevention and management.  Unhealthy lifestyles and relevant social determinants of disease should be identified and addressed where possible.  The recently developed American Heart Association PREVENT equations offer risk estimates for total CVD that include atherosclerotic CVD and heart failure. Individual therapies are available that simultaneously improve multiple disease states within CKM.  Pharmacotherapeutics with proven benefits in CKM syndrome include angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers, sodium-glucose cotransporter-2 inhibitors, the nonsteroidal mineralocorticoid receptor antagonist finerenone, and glucagon-like peptide 1 receptor agonists. 

KEYWORDS / КЉУЧНЕ РЕЧИ:

REFERENCES / ЛИТЕРАТУРА:

  • Sebastian SA, Padda I, Johal G. Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review. Curr Probl Cardiol. 2024;49(2):102344.
  • Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-35.
  • Yim Y, Lee JE, Son Y, Kim S, Lee H, Lee S, et al. Long-term trends in the prevalence of cardiovascular-kidney-metabolic syndrome in South Korea, 2011-2021: a representative longitudinal serial study. Lancet Reg Health West Pac. 2025;55:101474.
  • Despres JP, Carpentier AC, Tchernof A, Neeland IJ, Poirier P. Management of Obesity in Cardiovascular Practice: JACC Focus Seminar. J Am Coll Cardiol. 2021;78(5):513-31.
  • Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol [Internet]. 2025 January 2025. Available from: https://www.ncbi.nlm.nih.gov/pubmed/39824205.
  • Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res. 2014;164(4):323-35.
  • Gallo G, Savoia C. New Insights into Endothelial Dysfunction in Cardiometabolic Diseases: Potential Mechanisms and Clinical Implications. Int J Mol Sci. 2024;25(5).
  • Umbro I, Baratta F, Angelico F, Del Ben M. Nonalcoholic Fatty Liver Disease and the Kidney: A Review. Biomedicines. 2021;9(10).
  • Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020;22 Suppl 1:3-15.
  • Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. 2005;112(20):3066-72.
  • Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302-8.
  • Gonzalez-Perez A, Saez M, Vizcaya D, Lind M, Garcia Rodriguez L. Incidence and risk factors for mortality and end-stage renal disease in people with type 2 diabetes and diabetic kidney disease: a population-based cohort study in the UK. BMJ Open Diabetes Res Care. 2021;9(1).
  • Szlagor M, Dybiec J, Mlynarska E, Rysz J, Franczyk B. Chronic Kidney Disease as a Comorbidity in Heart Failure. Int J Mol Sci. 2023;24(3).
  • Speer T, Dimmeler S, Schunk SJ, Fliser D, Ridker PM. Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. Nat Rev Nephrol. 2022;18(12):762-78.
  • Barzilay JI, Farag YMK, Durthaler J. Albuminuria: An Underappreciated Risk Factor for Cardiovascular Disease. J Am Heart Assoc. 2024;13(2):e030131.
  • Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-305.
  • van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79(12):1341-52.
  • Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019;139(16):e840-e78.
  • International Cardiometabolic Working G, Krentz A, Jacob S, Heiss C, Sattar N, Lim S, et al. Rising to the challenge of cardio-renal-metabolic disease in the 21st century: Translating evidence into best clinical practice to prevent and manage atherosclerosis. Atherosclerosis. 2024;396:118528.
  • Thomas M, Magwire M, Gosch K, Sammour Y, Mehta R, O’Keefe J, et al. Cardiometabolic Center of Excellence: A Novel Care Delivery Model for Secondary Prevention of Cardiovascular Disease in Type 2 Diabetes. Circ Cardiovasc Qual Outcomes. 2021;14(10):e007682.
  • Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation. 2023;148(24):1982-2004.
  • Razavi AC, Kohli P, McGuire DK, Martin SS, Polonsky TS, McEvoy JW, et al. PREVENT Equations: A New Era in Cardiovascular Disease Risk Assessment. Circ Cardiovasc Qual Outcomes. 2024;17(4):e010763.
  • Kidney Disease: Improving Global Outcomes Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87.
  • Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR, et al. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation. 2020;142(17):e265-e86.
  • Seidu S, Alabraba V, Davies S, Newland-Jones P, Fernando K, Bain SC, et al. SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review. Diabetes Ther. 2024;15(5):1099-124.
  • Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45:2753-86.
  • Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-61.
  • Gonzalez-Juanatey JR, Gorriz JL, Ortiz A, Valle A, Soler MJ, Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med. 2023;55(1):502-13.
  • Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-84.
  • Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024;30(12):3758-64.
  • Abasheva D, Ortiz A, Fernandez-Fernandez B. GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity. Clin Kidney J. 2024;17(Suppl 2):19-35.
  • Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-21.
  • Badve SV, Bilal A, Lee MMY, Sattar N, Gerstein HC, Ruff CT, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15-28.
  • Vitale M, Haxhi J, Cirrito T, Pugliese G. Renal protection with glucagon-like peptide-1 receptor agonists. Curr Opin Pharmacol. 2020;54:91-101.
  • McGuire DK, Marx, N., Mulvagh,S.L., et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025. 1056/NEJMoa2501006